Rufinamide, Felbamate and Lacosamide in Serum/Plasma - HPLC

Order No.: 21000, for 100 tests
Parameters:
Eslicarbazepine, Felbamate, Lacosamide, N-Desmethylmesuximide, Rufinamide

No interference with concomitant drug therapy
Identical sample preparation to reagent kit order no. 22000
Option of combined analysis with 22000/F

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR-2022 regulation

Eslicarbazepine

Felbamate

Lacosamide

N-Desmethylmesuximide

Rufinamide

Clinical relevance

Rufinamide, felbamate and mesuximide are approved in the EU for concomitant therapy in combination with other antiepileptic drugs (AEDs). They are primarily used to treat therapy-resistant epilepsies and Lennox–Gastaut syndrome, and are also suitable for difficult to treat epilepsies in children. Rufinamide and felbamate influence the effectiveness of other AEDs and contraceptive products. Eslicarbazepine acetate and lacosamide are also used in combination with other AEDs to treat partial epileptic seizures.

The blood levels of these medications must be determined to maintain the therapeutic range due to their pharmacodynamics and toxicities. That also includes measuring the levels of the metabolites N-desmethyl mesuximide and eslicarbazepine.

 

Product advantages

  • Undisturbed analysis for comedication with other antiepileptics
  • Sample preparation is identical to the reagent kit "Antiepileptics for HPLC", # 22000
  • Combined analysis with 22000/F is possible

Enhanced HPLC analysis of the antiepileptics enables the reliable determination of the AEDs rufinamide, felbamate, lacosamide, eslicarbazepine and N-desmethyl mesuximide. Sample preparation requires only one precipitation step and is identical to that of the Chromsystems kit order no. 22000. It has been tested for interference from other AEDs and can therefore guarantee undisturbed analysis even in the case of concomitant therapy with other AEDs.

Our TDM Parameter Set Antiepileptic Drugs from the MassTox® TDM Series A is available as an alternative for the measurement of these analytes with LC-MS/MS.

More Information
Method of Analysis HPLC
Number of Tests 100
Limit of quantification

0.5–1.0 mg/l

Linearity

up to 200 mg/l

Recovery 100 %
Intraassay

CV < 2 %

Interassay

CV < 2 %

Analysis Time < 15 min
Specimen Serum/Plasma
Pre-analytic Treatment

Patient samples are stable up to 4 weeks at +2 to +8 °C. For longer storage (up to 12 weeks) keep samples below -18 °C.

Sample Preparation
  • Pipette 100 µl serum/plasma and 150 µl Internal Standard into a reaction vial.
  • Mix 2 s (vortex).
  • Add 50 µl Precipitation Reagent.
  • Mix 1 min (vortex).
  • Centrifuge 10 min at 15000 x g.
  • Mix 100 µl supernatant with 100 µl Stabilisation Buffer.
  • Inject 20 µl into the HPLC system.
Sample Stability At ambient temperature 1 week, at +2 to +8 °C 2 weeks and below -18 °C 3 weeks.
Injection Volume 20 µl
Flow rate 2.5 ml/min
Column temperature ambient temperature (~25 °C)
Wavelength 204 nm
Gradient isokratic
Additional Info Isocratic HPLC system with UV detector.

Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Parameter Eslicarbazepine, Felbamate, Lacosamide, N-Desmethylmesuximide, Rufinamide
As a customer please login or register to gain full access.